ROME Therapeutics to Participate in 2024 Wedbush PacGrow Healthcare Conference
August 12 2024 - 6:00AM
ROME Therapeutics, a biotechnology company harnessing the power of
the dark genome to develop breakthrough medicines for serious
diseases, today announced that Rosana Kapeller, M.D., Ph.D.,
President, Chief Executive Officer and Co-Founder of ROME, will
participate in a panel discussion at the Wedbush PacGrow Healthcare
Conference titled, “Case of Mistaken Identity: New Approaches in
Autoimmune,” on Wednesday, August 14th at 8:00 am ET. Management
will also be available for investor meetings at the conference.
About ROME
ROME Therapeutics is developing novel therapies for a range of
serious diseases, including autoimmune disease, cancer, and
neurodegeneration, by illuminating the role of the dark genome
— the vast genomic expanse beyond the traditional genes, which
includes virus-like repetitive elements and non-coding sequences —
in human health and disease. Leveraging the company’s unprecedented
data sciences platform, ROME has built a deep pipeline of therapies
targeting the dark genome. To lead this exploration, ROME has
assembled a team of world-class leaders in drug discovery and
development across immunology, oncology, chemistry, and machine
learning. ROME is based in Boston, Mass. For more information,
please visit www.rometx.com.
Investor ContactMonique AllaireTHRUST Strategic
Communicationsmonique@thrustsc.com
Media ContactLiz MeloneMelone
Communicationsliz@melonecomm.com